FOLH1 and pachyonychia congenita: More prospective trials with larger cohorts using GRPR antagonists are needed, especially in comparison to the currently most widely used 68Ga-PSMA-11, to better understand their relationship and potential predictive value of tumor biology and aggressiveness in different types and stages of PC.